YPEL inhibitors refer to a category of chemical compounds that modulate the function of Yippee-like (YPEL) proteins. The YPEL protein family consists of small, evolutionarily conserved proteins that have been identified across various species, including humans. This family of proteins has been associated with numerous cellular processes and has been implicated in various molecular pathways, which is why there's interest in understanding how their function can be altered or modulated. At the molecular level, YPEL proteins exhibit distinct structural motifs, which serve as targets for the binding of small molecules or other modulatory agents.
The development and study of YPEL inhibitors is primarily driven by the need to better understand the physiological and cellular roles of YPEL proteins. By introducing these inhibitors into biological systems, scientists can glean insights into the downstream effects and interplay between YPEL proteins and other cellular components. As with many molecular inhibitors, YPEL inhibitors are designed to bind selectively and with high affinity to their target proteins, ensuring that they act specifically on YPEL proteins and not on unrelated molecules. This specificity is crucial for understanding the direct impacts of YPEL modulation and for eliminating confounding variables in experimental setups. Chemical methods such as structure-based drug design, high-throughput screening, and molecular docking are typically employed to identify and optimize these inhibitors, ensuring their efficacy and selectivity towards the YPEL protein family. As the field advances, it's anticipated that the library of known YPEL inhibitors will expand, broadening our understanding of these intriguing proteins and their roles within cellular machinery.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $26.00 $119.00 $213.00 | 27 | |
Imatinib inhibits tyrosine kinases, particularly BCR-ABL, blocking phosphorylation of substrates and blocking cell proliferation. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
Gefitinib targets EGFR, inhibiting the autophosphorylation of the receptor, thereby suppressing cell growth and division. | ||||||
Ruxolitinib | 941678-49-5 | sc-364729 sc-364729A sc-364729A-CW | 5 mg 25 mg 25 mg | $251.00 $500.00 $547.00 | 16 | |
Ruxolitinib is a JAK1/JAK2 inhibitor that suppresses the JAK-STAT signaling pathway, reducing inflammation and cell proliferation. | ||||||
Suberoylanilide Hydroxamic Acid | 149647-78-9 | sc-220139 sc-220139A | 100 mg 500 mg | $133.00 $275.00 | 37 | |
Vorinostat inhibits histone deacetylases (HDACs), leading to increased histone acetylation and gene expression changes in cancer cells. | ||||||
Osimertinib | 1421373-65-0 | sc-507355 | 5 mg | $86.00 | ||
Osimertinib selectively targets mutant EGFR, blocking the signaling pathways responsible for cancer cell survival and growth. | ||||||
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $321.00 | ||
Palbociclib inhibits CDK4/6, preventing phosphorylation of the retinoblastoma protein and cell cycle progression in cancer cells. | ||||||
CH5424802 | 1256580-46-7 | sc-364461 sc-364461A | 5 mg 50 mg | $191.00 $902.00 | ||
Alectinib targets ALK, blocking the activation of downstream signaling pathways that promote cancer cell growth. | ||||||
ABT-199 | 1257044-40-8 | sc-472284 sc-472284A sc-472284B sc-472284C sc-472284D | 1 mg 5 mg 10 mg 100 mg 3 g | $118.00 $337.00 $520.00 $832.00 $1632.00 | 10 | |
Venetoclax inhibits BCL-2, promoting apoptosis in cancer cells by disrupting the regulation of mitochondrial outer membrane permeability. | ||||||
Ibrutinib | 936563-96-1 | sc-483194 | 10 mg | $156.00 | 5 | |
Ibrutinib inhibits BTK, disrupting B-cell receptor signaling and blocking the survival and proliferation of malignant B cells. | ||||||
Everolimus | 159351-69-6 | sc-218452 sc-218452A | 5 mg 50 mg | $131.00 $651.00 | 7 | |
Everolimus inhibits mTOR, a key regulator of cell growth and survival, thereby reducing cancer cell proliferation and angiogenesis. | ||||||